Clinical Trial Update: AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating AK105 plus anlotinib hydrochloride with albumin paclitaxel as first-line therapy for advanced triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Albumin Paclitaxel (nab-paclitaxel)
• Anlotinib hydrochloride (anlotinib)

Snippet

Sponsor: Liaoning Cancer Hospital & Institute | Conditions: Breast Neoplasm Female | Phase 2 | Status: UNKNOWN